Is COVID a Flu? Why They’re Two Different Diseases

COVID-19 and influenza are caused by entirely different viruses that belong to separate viral families, enter your cells through different doorways, and cause distinct patterns of illness and long-term damage. They can look alike on the surface because both are respiratory infections that spread through the air and share symptoms like fever, cough, and fatigue. But the similarities are largely superficial, and conflating the two has led to real misunderstandings about risk, treatment, and prevention.

Different Viruses, Different Blueprints

SARS-CoV-2, the virus behind COVID-19, is a coronavirus. Influenza is caused by influenza viruses, most commonly types A and B. These are not close relatives. They sit in completely different viral families, with fundamentally different genetic architectures. SARS-CoV-2 carries its genetic instructions on a single strand of RNA about 30,000 nucleotides long, read in the “positive-sense” direction, meaning the cell can start translating it into proteins almost immediately after infection. Influenza A, by contrast, stores its genome across eight separate RNA segments, all in the “negative-sense” direction, requiring an extra copying step before the cell’s machinery can read them.¹

This difference in genome structure matters beyond the biology lab. Influenza’s segmented genome is the reason the flu can undergo “reassortment,” where two different flu strains infecting the same cell swap entire gene segments and produce a dramatically new virus almost overnight. That is how pandemic flu strains have historically emerged. SARS-CoV-2 can’t do this. It mutates the old-fashioned way, through copying errors, and it actually makes far fewer of those errors than the flu does because its replication machinery has a built-in proofreading function. In cell-culture experiments, SARS-CoV-2’s average mutation rate was roughly 24-fold lower than influenza A’s.² Despite that slower error rate, SARS-CoV-2 still generated variants like Delta and Omicron that spread worldwide, partly because its massive genome gives it more total territory for consequential mutations, and partly because billions of simultaneous infections gave the virus enormous opportunity.

How They Get Into Your Cells

Once you inhale either virus, each one latches onto a different molecular handle on the surface of your cells. SARS-CoV-2 uses its spike protein to bind a receptor called ACE2, then fuses with the cell membrane to get inside.³ Influenza viruses use a different protein, hemagglutinin, to grab onto sialic acid residues on cell surfaces. These are completely unrelated entry pathways, which is why drugs designed to block one virus don’t block the other. Tamiflu, for example, targets an influenza enzyme called neuraminidase and does nothing against SARS-CoV-2. Paxlovid blocks a SARS-CoV-2 protease and has no effect on flu.

The ACE2 receptor targeted by SARS-CoV-2 is found on cells throughout the body, not just in the airways. It sits on cells lining blood vessels, the heart, kidneys, gut, and brain. That broad tissue access helps explain why COVID-19 can affect so many organs beyond the lungs. Influenza viruses are more narrowly targeted to the respiratory tract, though severe flu can also damage the heart and other organs in extreme cases.

Overlapping Symptoms, But Key Differences

Both infections can cause fever, body aches, cough, sore throat, and fatigue. In a mild case, you might not be able to tell the two apart without a test. But certain symptoms show up far more often with one virus than the other.

Loss of smell and taste became one of the hallmark signs of COVID-19, especially with earlier variants. A study comparing the two infections in matched populations found that smell and taste disorders occurred about 11 times more frequently after COVID-19 than after influenza.⁴ While this gap narrowed with Omicron and later variants, it still illustrates that the two viruses do different things to the body. Influenza, meanwhile, tends to hit harder and faster with muscle pain and high fevers that come on suddenly, while COVID-19 has a more gradual onset and a broader symptom range that can include shortness of breath, brain fog, and gastrointestinal symptoms.

The incubation period differs too. Flu symptoms usually appear one to four days after exposure. COVID-19 typically takes longer, with symptoms showing up two to fourteen days later, depending on the variant. That longer incubation window gave early COVID-19 a transmission advantage: people had more time to unknowingly spread the virus before feeling sick.

Viral Shedding and When You’re Contagious

A systematic review of shedding data found that SARS-CoV-2 RNA was detectable in the upper respiratory tract for an average of 17 days, with a maximum of 83 days in some individuals.⁵ However, live virus capable of actually infecting someone else was not recovered beyond about nine days of illness, even though RNA continued to show up on tests. This is an important distinction: a positive PCR test doesn’t necessarily mean you’re still contagious. SARS-CoV-2 viral load appeared to peak in the first week of illness, meaning people were most infectious early on, often before or just as symptoms appeared.⁵

Influenza also peaks early but has a shorter overall shedding window. Most adults clear infectious flu virus within about five to seven days, and the period of peak contagiousness usually lines up with the worst symptoms. This difference in timing is part of why COVID-19 was so hard to contain with symptom-based screening: by the time someone felt sick enough to stay home, they had already been spreading the virus for days.

Mortality Is Not Even Close

The question of severity has been the most politically charged part of the COVID-flu comparison. Early in the pandemic, some dismissed COVID-19 as “just the flu.” The data have consistently shown otherwise.

A study of U.S. veterans aged 65 and older found that crude 30-day mortality among those hospitalized with COVID-19 was about 19%, compared to roughly 4% for influenza. The odds of dying within 30 days were more than six times higher for the COVID-19 group.⁶ A separate, more recent analysis that adjusted for age, sex, and underlying conditions still found COVID-19 associated with significantly higher 30-day mortality compared with seasonal influenza, with particularly elevated risk among hospitalized patients and younger adults aged 18 to 64.⁷

Hospitalization rates told a similar story. During the fall–winter 2022–2023 season, after vaccines and prior infections had built substantial population immunity, COVID-19 still drove hospitalization rates roughly four to six times higher than influenza across all adult age groups.⁸ These were not early-pandemic numbers inflated by a naive immune population; this was the comparison after widespread Omicron exposure and vaccination campaigns.

Long-Term Damage and Readmission Risk

The damage from COVID-19 doesn’t necessarily end when the acute infection clears. Research comparing long-term outcomes after hospital admission for COVID-19 versus seasonal influenza found that COVID-19 patients faced a meaningfully higher rate of hospital readmission, with roughly 20 excess readmissions per 100 people, and about 9 excess intensive-care admissions per 100 people, compared with influenza patients.⁹

Cardiovascular risk, in particular, appears to remain elevated for at least a year after a COVID-19 infection, regardless of whether someone had heart problems beforehand.¹⁰ SARS-CoV-2’s ability to damage the endothelium, the thin lining of blood vessels, appears to drive much of this lasting cardiovascular harm. Influenza can stress the heart, and severe flu is a recognized trigger for heart attacks, but the breadth and duration of vascular damage seen after COVID-19 goes beyond what researchers have documented with the flu.

The term “long COVID” has entered everyday language to describe persistent symptoms like fatigue, brain fog, and exercise intolerance lasting months after infection. Influenza can also lead to post-viral syndromes, and a review of post-viral conditions in children and adolescents found that the duration of lingering symptoms was actually similar for post-COVID and post-Epstein-Barr virus syndromes, ranging from days to 18 months.¹¹ So prolonged post-viral illness is not unique to COVID-19. What distinguishes long COVID is its scale: because so many people were infected so rapidly, the absolute number of people left with persistent symptoms dwarfed what any single flu season has produced.

Seasonality and Why COVID Doesn’t Follow the Flu Calendar

Seasonal flu follows a fairly predictable pattern in temperate climates: cases rise in autumn, peak in winter, and fade by spring. People often assume COVID-19 will settle into the same rhythm. The evidence so far suggests it hasn’t, at least not cleanly.

An analysis of multi-year surveillance data found that SARS-CoV-2 shows what the authors called “seasonal divergence.” In temperate climates, it does tend to surge in winter. But in tropical regions, consistent summer surges have been observed. The proposed explanation is that extreme heat drives people indoors and into air-conditioned spaces, recreating the same kind of crowded, poorly ventilated environments that fuel winter transmission in colder climates.¹² SARS-CoV-2 also appears more thermally resilient than influenza and transmits efficiently before symptoms appear, giving it the ability to persist outside classical winter bounds.¹²

For practical purposes, this means you can’t rely on the season to gauge your COVID-19 risk the way you can roughly estimate flu risk. Summer waves have caught people off guard repeatedly, and the timing of new variant waves hasn’t neatly aligned with the traditional respiratory virus season.

Immunity Fades Differently

After a bout of seasonal flu, your immunity to that specific strain tends to be strong and fairly durable. The challenge with flu is not waning immunity to a known strain but the emergence of a new strain each season through its rapid mutation and reassortment. That is why the flu vaccine is reformulated annually.

With SARS-CoV-2, immunity wanes on both fronts. Protection from a pre-Omicron infection against reinfection with the same pre-Omicron lineages peaked at about 90% around the seventh month, then dropped to roughly 70% by 16 months and was estimated to fall below 50% by about 22 months.¹³ When a new variant like Omicron arrived, protection from a prior pre-Omicron infection dropped to about 38%, illustrating both immune escape from a new variant and general immune waning.¹³ This pattern of relatively rapid reinfection has been one of the defining features of the pandemic and part of the reason COVID-19 kept producing wave after wave even in populations with high prior exposure.

What Happens When You Get Both at Once

Because both viruses circulate during overlapping periods, co-infection is a real possibility. And it’s worse than getting either one alone. Animal studies modeling simultaneous SARS-CoV-2 and influenza A infection found that co-infection prolonged the duration of both infections, increased inflammatory damage in the lungs, and led to more severe pneumonia. Co-infected animals also showed significantly fewer virus-specific and neutralizing antibodies than those with a single infection, suggesting the immune system was essentially overwhelmed and couldn’t mount an effective response against either virus individually.¹⁴ Mortality was higher in the co-infected group as well.

This finding has practical implications. Getting vaccinated against both viruses isn’t just doubling down for the sake of caution. It reduces the chance of the worst-case scenario where two different viral infections compound each other’s damage. Public health agencies have increasingly encouraged getting flu and COVID-19 vaccines in the same visit during autumn for exactly this reason.

How COVID-19 Affects Children Differently Than Flu

Early in the pandemic, a comforting narrative took hold that children were largely spared by COVID-19. That was true in a relative sense: children were far less likely than older adults to be hospitalized or die. But COVID-19 introduced a complication in children that has no flu equivalent: multisystem inflammatory syndrome in children, or MIS-C.

MIS-C typically appeared two to six weeks after a SARS-CoV-2 infection and caused widespread inflammation affecting the heart, lungs, kidneys, brain, skin, and gastrointestinal system. In a Canadian study, about half of children hospitalized with MIS-C required intensive care, compared to about 18% of those hospitalized with acute COVID-19.¹⁵ Cardiac involvement was strikingly common in MIS-C, affecting more than 80% of patients in one study, compared to under 10% of children with acute COVID-19.¹⁶

Influenza in children can be severe and occasionally fatal, especially in very young children and those with underlying conditions. But MIS-C has no established equivalent triggered by influenza. Cases of MIS-C have dropped substantially with increasing immunity from vaccination and prior infection, but its existence underscored a real and measurable difference between these two infections in the pediatric population.

Why the Confusion Persists

Several factors keep the “COVID is just the flu” idea alive. The first is genuine symptom overlap. If you’ve had a mild case of each, they may have felt indistinguishable, and personal experience is powerful. The second is the evolving severity landscape: as Omicron became dominant and population immunity grew, the gap in severity between COVID-19 and influenza narrowed in many individual cases, making it easy to assume the two diseases were always similar. But narrowing severity in a highly immune population is not the same as the diseases being equivalent. A vaccinated person’s mild COVID-19 and a vaccinated person’s mild flu may feel the same, but the underlying biology, the risk to unvaccinated or immunocompromised people, and the potential for organ damage beyond the lungs remain distinct.

The confusion is also partly linguistic. “Flu” is used casually in English to describe any short respiratory illness, including the common cold. When people say “I had the flu,” they often mean something much milder than actual influenza. This muddying of terms makes it harder to have a precise conversation about how COVID-19 compares to true, confirmed influenza infection.

Treatments Target Different Machinery

Because the two viruses replicate using different enzymes and enter cells through different receptors, the antivirals developed for each one are not interchangeable. Oseltamivir (Tamiflu) and baloxavir (Xofluza) work specifically against influenza’s neuraminidase or endonuclease. Nirmatrelvir/ritonavir (Paxlovid) and remdesivir target SARS-CoV-2’s protease and RNA polymerase. Taking Tamiflu for a COVID-19 infection would be useless, and vice versa. This is one of the most practical reasons the distinction matters: knowing which virus you have determines which treatment can help. Rapid combination tests that detect both SARS-CoV-2 and influenza from a single swab are now widely available and can guide treatment decisions within minutes.

The proofreading ability of SARS-CoV-2 mentioned earlier has an interesting drug-development implication as well. Because the virus has a built-in error-correction mechanism, antiviral drugs that work by introducing lethal mutations into the viral genome, a strategy called lethal mutagenesis, face a higher bar against SARS-CoV-2 than against influenza.¹⁷ This has shaped which drug candidates advanced through development for each virus.